{"id":"NCT04285229","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis","officialTitle":"A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial Spondyloarthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-04-10","primaryCompletion":"2021-03-31","completion":"2022-03-17","firstPosted":"2020-02-26","resultsPosted":"2022-06-28","lastUpdate":"2023-04-14"},"enrollment":147,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Spondyloarthritis"],"interventions":[{"type":"DRUG","name":"Ixekizumab","otherNames":["LY2439821"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ixekizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in Chinese participants with radiographic axial spondyloarthritis (r-axSpA).","primaryOutcome":{"measure":"Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response in Biological Disease-modifying Antirheumatic Drug (bDMARD)-na√Øve Participants","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo","deltaMin":7.8,"sd":null},{"arm":"Ixekizumab 80mg Q4W","deltaMin":40.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":19,"countries":["China"]},"refs":{"pmids":["40343690","38907104","37737952"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":73},"commonTop":["Upper respiratory tract infection","Injection site reaction","Hyperuricaemia","Hepatic function abnormal","Blood creatine phosphokinase increased"]}}